Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
99283-10-0
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)immunostimulant
Mechanism of action
Binds GM-CSF receptors and restores GM-CSF signalling, supporting proliferation and differentiation of haematopoietic progenitor cells and activation of neutrophils, monocytes, macrophages and dendritic cells.
Indications / reported uses
Investigational inhaled treatment of pulmonary alveolar proteinosis and other studied pulmonary indications; do not interpret this entry as a universal marketing authorisation.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Molgramostim PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Molgramostim Permitted Daily Exposure (PDE) report (the Molgramostim PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Molgramostim Occupational Exposure Limit (OEL) report (the Molgramostim OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.